Patients Chronic kidney disease: treating a silent killer In November, NICE backed NHS use of AstraZeneca’s diabetes and heart failure drug Forxiga for the treatment of chronic kidney disease.
Views & Analysis AstraZeneca on expanding its diabetes research franchise AstraZeneca is hoping to build a strong focus on cardiovascular, renal, and metabolic (CVRM) diseases.
News Bausch Health hit as Xifaxan successor flunks trials A hole has been blown in Bausch Health's late-stage pipeline, after a follow-up to its top-selling drug product Xifaxan failed two phase 3 trials.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.